Technology
ProUroCare Medical Inc.(PUMD)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → May 29, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- -30.8%
- Dividend Yield
- 0.0%
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProUroCare Medical Inc. (PUMD) is a Technology stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -30.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -30.8%, free cash flow -34.9% with operating margin 0.0% and ROIC 78.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PUMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +11.9% peer median
Operating Margin
Below sector median
0.0% vs +22.0% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -30.8%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PUMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PUMD Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PUMD and SPY.
Company Overview
ProUroCare Medical Inc.
Other OTC
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
- Leadership
- Benjamin Banks
- IPO Date
- Nov 29, 2022
- Employees
- 2
- Street Address
- 6440 Flying Cloud Drive
- Mailing
- Eden Prairie
- Region
- Eden Prairie, US
- Reporting Currency
- USD
- Investor Line
- +1 952 746 1555
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- -30.8%
- Free Cash Flow
- -34.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 90.3%
- ROIC
- 78.7%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.